The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Fund Price: $11.88 (as at September 22, 2017)  1-day chg: $-.0161 -0.14%  YTD: 7.18%

Returns as at August 31, 2017

  Fund Group Avg Index*
1 Month 1.61% 1.13% 0.67%
3 Months -4.86% -2.73% -0.15%
6 Months 2.50% 5.21% 0.28%
1 Year 5.24% 11.77% 7.23%
2 Year Avg 6.06% 9.29% 7.96%
3 Year Avg - 12.82% 2.10%
4 Year Avg - 16.03% 7.85%
5 Year Avg - 17.40% 8.13%
10 Year Avg - 9.05% 4.10%
15 Year Avg - 9.05% 8.54%
20 Year Avg - 7.25% 6.74%
Since Inception 10.12% - -
 
2016 -4.85% 0.11% 21.08%
2015 27.91% 17.95% -8.32%
2014 - 19.62% 10.55%
 
3 year risk - 14.30 7.65
3 year beta - 0.50 1.00

*S&P/TSX Total Return

Growth of $10,000

This graph shows how a $10,000 investment in this fund would have changed in value compared with the S&P/TSX Total Return.

Risk Measures as at August 31, 2017

Best/Worst 12 months (since inception)
Best (ending Dec 15): 27.91 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
Worst (ending Dec 16): -4.85 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
Volatility meter (Based on 2 year standard deviation from GlobeInvestor.com)
Low VOLATILITY METER: 11 High

Fund Objectives

The fund's investment objectives to provide holders of units with: (i) stable monthly cash distributions; and (ii) long-term total return through distribution and capital appreciation of the Fund's investment portfolio; by utilizing an investment strategy which combines passive and active portfolio management and focuses on investing in dividend-paying securities of global issuers that derive a significant portion of their revenue or earnings from products or services related to healthcare.

Fund Facts

Fund Sponsor: Middlefield Group Limited
Managed by: Middlefield Group Limited
Fund Type: MF Trust
Inception Date: October 2014
Asset Class: Sector Equity
Quartile Rank: - (3YR ending August 31, 2017)
Total Assets: N/A
Mgmt Exp. Ratio (MER): 1.83%
Management Fee: 2.00%
Load Type: No Load
Globe 5-Star Rating:
RRSP Eligible:
Canadian
Min. Invest (initial):
-
Subsequent:
-
Min. Invest (initial RRSP):
-
Subsequent RRSP:
-
Closed:
No
Restricted:
No
Restriction:
 
 

Asset Allocation August 31, 2017

Equity Sector Weightings August 31, 2017

Fund Geography August 31, 2017

Top Holdings as at August 31, 2017

Symbol Company Name Sector Geographic
Area
Asset
Type
% of
Total Assets
  Performance as at September 22, 2017
1 Year Performance (%)
BMY-N Bristol Myers Squibb Biotechnology & Pharmaceuticals United States Stock 6.08   12.3 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
VRTX-Q Vertex Pharmaceuticals Biotechnology & Pharmaceuticals United States Stock 5.76   64.2 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
UNH-N UnitedHealth Group Medical Services United States Stock 5.71   36.86 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
- Roche Holdings Biotechnology & Pharmaceuticals Switzerland Stock 5.1   - bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
BSX-N Boston Scientific Biotechnology & Pharmaceuticals United States Stock 4.95   21.58 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
TMO-N Thermo Fisher Scientific Electrical & Electronic United States Stock 4.84   19.43 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
MRK-N Merck & Company Biotechnology & Pharmaceuticals United States Stock 4.59   3.35 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
- CSL Ltd Biotechnology & Pharmaceuticals Australia Stock 4.39   - bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
BDX-N Becton Dickinson Biotechnology & Pharmaceuticals United States Stock 4.3   6.34 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)
XRAY-Q DENTSPLY SIRONA Inc. - United States Stock 3.66   -2.47 bar graph of the performance of this holding (negative result) bar graph of the performance of this holding (positive result)

Distribution Report (18 months up to September 22, 2017)

Frequency of Income Distributions: None

Frequency of Capital Gain Distributions: None

Date Income Dividend Capital Gain Total (Current Period) Trailing 12-Months Total Reinvestment Price
Mar 31, 2017 0.0800 0.0800 0.4134 11.874
Nov 30, 2016 0.0417 0.0417 0.5000 11.078
Oct 31, 2016 0.0417 0.0417 0.5000 10.962
Sep 30, 2016 0.0417 0.0417 0.5000 11.520
Aug 31, 2016 0.0417 0.0417 0.5000 11.580
Jul 29, 2016 0.0417 0.0417 0.5000 12.056
Jun 30, 2016 0.0417 0.0417 0.5000 11.721
May 31, 2016 0.0417 0.0417 0.5000 11.629
Apr 29, 2016 0.0417 0.0417 0.5000 11.069
Mar 31, 2016 0.0417 0.0417 0.5000 11.053

Portfolio Manager(s)

Dean Orrico, Mike Bury

Middlefield Group Limited

Start Date: October, 2014

Fund Return: 12.43%

Also manages:Global Healthcare Dividend Series F

View fund manager performance report